What is the appropriate evaluation and treatment for recurrent self‑healing keratoacanthomas on the legs?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Overview of Recurrent Self-Healing Keratoacanthomas on the Legs

Recurrent keratoacanthomas (KAs) on the legs represent a challenging clinical entity requiring careful evaluation and treatment selection, with surgical excision remaining the gold standard despite their self-healing nature, though intralesional methotrexate offers an effective alternative for recurrent or multiple lesions.

Clinical Presentation and Diagnosis

Keratoacanthomas are now classified as clinically and pathologically distinctive, self-limiting squamous tumors of infundibular-trichilemmal origin characterized by rapid growth, stabilization, and spontaneous regression, often leaving deep scars 1. They typically manifest as solitary dome-shaped nodules capped with central keratin on sun-exposed areas 1.

Key diagnostic features include:

  • Rapid growth phase (weeks to months)
  • Dome-shaped architecture with central keratotic crater
  • Well-demarcated borders with rolled edges
  • Tendency for spontaneous regression over 3-6 months
  • Scarring after resolution

Dermatoscopic Features

Well-differentiated KAs show white-predominant coloration including keratin masses, white structureless areas, white perifollicular circles, and white perivascular halos surrounding hairpin or coiled vessels 1. These features help distinguish KAs from other nodular tumors.

Critical Diagnostic Caveat

Despite their classification as distinct from invasive cutaneous squamous cell carcinoma (CSCC) in the WHO 5th edition 1, KAs can be histologically indistinguishable from well-differentiated CSCC and some demonstrate aggressive behavior. Biopsy confirmation is essential, particularly for atypical presentations or lesions on the extremities 2.

Treatment Approach for Recurrent Leg KAs

First-Line Treatment: Surgical Excision

Surgery remains the treatment of choice for most KAs 2, particularly for recurrent lesions. For leg KAs, standard excision with 4-6 mm clinical safety margins is appropriate for low-risk lesions 3. The European consensus guidelines recommend surgical excision as primary treatment with post-operative pathologic margin assessment 3.

Surgical considerations:

  • Complete excision with adequate margins (4-6 mm for low-risk features)
  • Histological confirmation of clear margins
  • Reconstructive planning for larger defects
  • Higher recurrence risk necessitates careful margin assessment

Second-Line: Intralesional Methotrexate

For recurrent, multiple, or cosmetically sensitive leg KAs, intralesional methotrexate (MTX) represents an excellent alternative with 71-100% resolution rates 3. A recent prospective trial demonstrated 56% pathological complete response with neoadjuvant MTX in CSCC 3, and retrospective data shows 88.9% complete resolution for KAs specifically 4.

MTX protocol:

  • Initial debulking of the lesion
  • 12.5-25 mg per injection at the base
  • Weekly injections for 2-4 treatments typically required 4
  • Particularly effective for extremity lesions 4
  • Average follow-up shows no recurrences at 2.8 years 4

Alternative Modalities for Recurrent Disease

When conventional surgery fails or is not cosmetically acceptable:

Intralesional 5-fluorouracil (5-FU):

  • 92% resolution rate in largest cohort 3
  • 50 mg/ml concentration, maximum 150 mg dose
  • May require multiple treatments (24% need >1 session) 3
  • Only 1% recurrence in responders 3

Combined Er:YAG laser with topical 5-FU:

  • Effective for giant recurrent KAs on legs 5
  • Four treatment sessions achieved tumor-free status
  • Complete epithelialization in 9 weeks 5
  • No recurrence at 6 months 5

Electrochemotherapy (ECT):

  • Effective for eruptive painful KAs on lower limbs 6
  • Rapid clinical regression with single session
  • Excellent for multiple lesions with limited side effects 6
  • Significant quality of life improvement 6

Systemic Therapy for Multiple Recurrent KAs

For patients with multiple recurrent KAs on legs:

  • Oral retinoids (isotretinoin 40 mg/day or acitretin 25-35 mg/day) 7
  • Topical tazarotene 0.1% gel for persistent lesions 7
  • Combination approach shows regression of most lesions
  • Particularly useful for eruptive variants

Adjuvant topical tretinoin after surgical excision:

  • Applied once daily for 3 months post-operatively 8
  • Prevents recurrence in high-risk cases 8
  • Good outcomes at 2-year follow-up 8

Critical Management Pitfalls

The European guidelines explicitly state that destructive modalities (cryotherapy, PDT, lasers) should NOT be performed for invasive CSCC 3, and given the diagnostic overlap between KA and CSCC, these should be avoided as primary treatment for KAs unless:

  • Lesions are small and multiple
  • Surgery/RT not possible
  • Unacceptable surgical consequences 3

The lack of histological control with destructive methods raises concern for recurrences and potentially more difficult subsequent surgery 3.

Recommended Algorithm for Recurrent Leg KAs

  1. Confirm diagnosis: Biopsy to distinguish from invasive CSCC
  2. First recurrence: Re-excision with adequate margins (4-6 mm) and histological confirmation
  3. Second recurrence or multiple lesions: Consider intralesional MTX (2-4 weekly injections of 12.5-25 mg)
  4. Persistent/refractory disease: Intralesional 5-FU or combined Er:YAG laser with topical 5-FU
  5. Multiple eruptive KAs: Systemic retinoids with topical tazarotene
  6. Post-surgical adjuvant: Topical tretinoin daily for 3 months to prevent recurrence

For elderly patients with comorbidities or those declining surgery, topical immunomodulation may be considered 9, though this represents an evolving approach with limited evidence.

Related Questions

A 71-year-old patient with autoimmune hepatitis in remission (normal liver function tests) who was switched from azathioprine to mycophenolate mofetil has now developed invasive squamous cell carcinoma of the skin; what management steps should be taken?
In an older patient with a solitary, centrally keratin‑filled crater‑like lesion on the arm, can dermoscopy reliably distinguish keratoacanthoma from squamous cell carcinoma, is it associated with systemic lupus erythematosus or immunodeficiency, does rapid emergence of multiple similar lesions suggest an underlying systemic malignancy, and should the patient be referred promptly because of the risk of bone invasion?
What is the classification and treatment of incydentaloma?
What is the recommended treatment for Keratoacanthoma?
What is the standard treatment approach for a newly diagnosed osteosarcoma, including chemotherapy, surgery, and follow‑up?
How much diluent should be used for a 2000 mg intravenous dose of Keppra (levetiracetam)?
In patients with severe dengue, what is the role of calcium gluconate and when should it be administered?
In a 40-year-old patient with chronic kidney disease receiving a nicardipine infusion (started at 5 mg/hr and titrated up to ≤15 mg/hr), is rebound hypotension expected after discontinuation?
Can immediate-release atenolol tablets be crushed and mixed with water for administration?
What are the recommended prenatal and postnatal management steps for a fetus diagnosed with compound heterozygous β⁺/β⁺ HbE‑β thalassemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.